WORLDSymposium 2026 Feb 2 - Feb 6, 2026 Supporting Materials Isaralgagene civaparvovec (ST-920) shows positive mean annualized eGFR slope in adults with Fabry disease: Topline results from the registrational Phase 1/2 STAAR gene therapy study and long-term follow-up study 744.3 KB Isaralgagene civaparvovec (ST-920) shows stable cardiac function over one year in patients with Fabry disease: Results from the registrational Phase 1/2 STAAR gene therapy study 664.2 KB Isaralgagene civaparvovec (ST-920) gene therapy for adults with Fabry disease: Pharmacology and immunogenicity outcomes from the Phase 1/2 STAAR study and ongoing long-term follow-up 1 MB A combined fertility, embryofetal development, AAV integration and germline transmission risk study in mice with ST-920 (isaralgagene civaparvovec) for Fabry disease 297.3 KB
Isaralgagene civaparvovec (ST-920) shows positive mean annualized eGFR slope in adults with Fabry disease: Topline results from the registrational Phase 1/2 STAAR gene therapy study and long-term follow-up study 744.3 KB
Isaralgagene civaparvovec (ST-920) shows stable cardiac function over one year in patients with Fabry disease: Results from the registrational Phase 1/2 STAAR gene therapy study 664.2 KB
Isaralgagene civaparvovec (ST-920) gene therapy for adults with Fabry disease: Pharmacology and immunogenicity outcomes from the Phase 1/2 STAAR study and ongoing long-term follow-up 1 MB
A combined fertility, embryofetal development, AAV integration and germline transmission risk study in mice with ST-920 (isaralgagene civaparvovec) for Fabry disease 297.3 KB